TheNewswire · 2 Sept 2026positive
SciSparc's subsidiary NeuroThera Labs announced it is pursuing FDA Orphan Drug Designation for SCI-110, its drug candidate for treating adults with Tourette Syndrome, and has engaged government and public affairs firm RK Strategies to strengthen its U.S. market position and visibility among federal stakeholders.
Why it matters — Securing Orphan Drug Designation could provide regulatory and market advantages for NeuroThera's lead CNS candidate, advancing a key development milestone for SciSparc's pipeline.
TheNewswire · 2 Sept 2026positive
SciSparc's subsidiary NeuroThera Labs announced it is pursuing FDA Orphan Drug Designation for SCI-110, its drug candidate for treating adults with Tourette Syndrome, and has engaged the government and public affairs firm RK Strategies to strengthen its U.S. market position and visibility among federal stakeholders.
Why it matters — This marks a strategic step for NewroThera toward advancing SCI-110 for adult Tourette Syndrome, potentially enhancing the subsidiary's regulatory prospects and U.S. presence.
GlobeNewsWire · 31 Aug 2026positive
SciSparc announced that its subsidiary NeuroThera Labs Inc. has continued advancing participant enrollment in the clinical trial evaluating its SCI-210 treatment for symptoms associated with autism spectrum disorder. The announcement updates progress on the company's investigative CNS therapy.
Why it matters — For SPRC watchers, progress in NeuroThera's SCI-210 clinical trial reflects continued development momentum for a key pipeline program within the company's subsidiary.
TheNewswire · 31 Aug 2026positive
NeuroThera Labs Inc., a subsidiary of SciSparc Ltd., announced continued advancement in participant enrollment for its clinical trial of SCI-210, a treatment for symptoms of autism spectrum disorder. The double-blind, randomized, placebo-controlled study at Soroka Medical Center in Israel has so far enrolled 26 of a planned 60 children aged five to 18, each receiving treatment over a 20-week period.
Why it matters — SPRC watchers would follow the enrollment progress of this clinical trial at NeuroThera, a wholly owned subsidiary, as it reflects the development status of a key pipeline asset in SciSparc's portfolio.
TheNewswire · 28 Aug 2026neutral
Neurothera Labs Inc., a subsidiary of SciSparc Ltd., announced it will consolidate its outstanding common shares on a one-for-fourteen basis, following a shareholder resolution passed in January 2026. The company stated the consolidation could raise its share trading price, potentially broadening its investor pool and helping it satisfy minimum trading price requirements for a possible U.S. listing.
Why it matters — SciSparc watchers would care because this corporate action by its subsidiary Neurothera could affect the value and market positioning of the assets held under SciSparc.
